Brief: Actinium Announces Oral Presentation at ASH Annual Meeting Highlighting Iomab-B Treatment
02/11/2023 13:17
Nov 2 (Reuters) - Actinium Pharmaceuticals Inc ATNM.A :
* ACTINIUM ANNOUNCES ORAL PRESENTATION AT ASH ANNUAL MEETING
HIGHLIGHTING IOMAB-B TREATMENT SIGNIFICANTLY INCREASED MEDIAN
OVERALL SURVIVAL IN RELAPSED OR REFRACTORY AML PATIENTS WITH
HIGHLY UNFAVORABLE TP53 GENE MUTATION IN THE PHASE 3 SIERRA
TRIAL
* ACTINIUM PHARMACEUTICALS INC - MAINTAINS ITS PRIOR CASH
RUNWAY
GUIDANCE THROUGH YEAR-END 2025 BASED ON ITS CURRENT OPERATING
PLAN
Source text for Eikon: ID:nPn8fj8vsa
Further company coverage: ATNM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities